1 https://www.crohnscolitisfoundation.org/what-is-crohns-disease/overview
2 https://effectivehealthcare.ahrq.gov/products/crohns-disease/research-protocol
3 https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf
4 https://www.genome.gov/Genetic-Disorders/Crohns-Disease
5 https://www.gastrojournal.org/article/S0016-5085(20)35312-9/fulltext
The LATITUDE CD Study is evaluating the efficacy and safety of an investigational oral treatment for Crohn’s disease. Participants will receive the investigational treatment or a placebo (a substance that looks like the investigational treatment but does not contain any active ingredients) while completing various study tests and procedures.
Participants originally assigned to placebo who still have disease worsening after the 12-week induction phase will have the opportunity to switch to the investigational treatment. All study treatments will be given as oral pills.
Neither participants nor the study staff will know if participants are receiving the investigational treatment or a placebo. Participants will attend up to 14 scheduled study visits (and any additional study visits if needed) over the course of about a year.